Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Acta Angiologica
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Publisher's Jubilee Conference Abstracts Reviewers 2022

open access

Vol 14, No 3 (2008)
Review paper
Published online: 2008-08-10
View PDF (Polish) Download PDF file
Get Citation

Resistance to acetylsalicylic acid - pathophysiology and clinical implications

Adrian Doroszko, Katarzyna Podgórska, Katarzyna Drożdż, Andrzej Szuba
Acta Angiologica 2008;14(3):79-87.

open access

Vol 14, No 3 (2008)
Review papers
Published online: 2008-08-10

Abstract

Cardiovascular diseases are the most common cause of morbidity and mortality. Acetylsalicylic acid (ASA) is an effective antiplatelet drug which decreases the risk of myocardial infarction, stroke and sudden death by 25% in groups with higher cardiovascular risk. The high efficacy of ASA in primary and secondary prevention of cardiovascular events might be diminished in cases of ASA resistance, as reported in 5-45% of patients. Acetylsalicylic acid resistance is diagnosed by clinical symptoms (thrombotic event during ASA therapy) or markers of platelet aggregation. Small observational have studies revealed higher cardiovascular risk in populations with ASA resistance. Beyond incomplete inhibition of COX-1, mechanisms of ASA resistance are still not well known. Duration of therapy, lack of compliance and drug interactions are considered as possible factors in the development of ASA resistance. Our review describes all known mechanisms of ASA resistance and their clinical consequences. We have also pointed out the need for the development of universally accepted diagnostic criteria and screening guidelines for ASA resistance.

Abstract

Cardiovascular diseases are the most common cause of morbidity and mortality. Acetylsalicylic acid (ASA) is an effective antiplatelet drug which decreases the risk of myocardial infarction, stroke and sudden death by 25% in groups with higher cardiovascular risk. The high efficacy of ASA in primary and secondary prevention of cardiovascular events might be diminished in cases of ASA resistance, as reported in 5-45% of patients. Acetylsalicylic acid resistance is diagnosed by clinical symptoms (thrombotic event during ASA therapy) or markers of platelet aggregation. Small observational have studies revealed higher cardiovascular risk in populations with ASA resistance. Beyond incomplete inhibition of COX-1, mechanisms of ASA resistance are still not well known. Duration of therapy, lack of compliance and drug interactions are considered as possible factors in the development of ASA resistance. Our review describes all known mechanisms of ASA resistance and their clinical consequences. We have also pointed out the need for the development of universally accepted diagnostic criteria and screening guidelines for ASA resistance.

Full Text:

View PDF (Polish) Download PDF file
Get Citation

Keywords

ASA resistance; acetylsalicylic acid; cyclooxygenase; thromboxane; cardiovascular diseases

About this article
Title

Resistance to acetylsalicylic acid - pathophysiology and clinical implications

Journal

Acta Angiologica

Issue

Vol 14, No 3 (2008)

Article type

Review paper

Pages

79-87

Published online

2008-08-10

Page views

974

Article views/downloads

1872

Bibliographic record

Acta Angiologica 2008;14(3):79-87.

Keywords

ASA resistance
acetylsalicylic acid
cyclooxygenase
thromboxane
cardiovascular diseases

Authors

Adrian Doroszko
Katarzyna Podgórska
Katarzyna Drożdż
Andrzej Szuba

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl